| Female |
68 (44.7%) |
10 (34.5%) |
0.307 |
| Age, yrs |
72.8 ± 6.1 |
74.1 ± 6.8 |
0.339 |
| Body mass index, kg/m2
|
22.6 ± 3.8 |
22.6 ± 2.9 |
0.969 |
| STS score, % |
6.1 ± 4.3 |
7.4 ± 4.0 |
0.115 |
| NYHA class > 2 |
133 (87.5%) |
25 (86.2%) |
0.768 |
| Hypertension |
58 (38.2%) |
12 (41.4%) |
0.744 |
| Diabetes mellitus |
30 (19.7%) |
5 (17.2%) |
0.755 |
| Chronic obstructive pulmonary disease |
68 (44.7%) |
16 (55.2%) |
0.302 |
| Coronary artery disease |
54 (35.5%) |
13 (44.8%) |
0.342 |
| Peripheral vessel disease |
59 (38.8%) |
13 (44.8%) |
0.544 |
| Cerebrovascular disease |
29 (19.1%) |
6 (20.7%) |
0.840 |
| Creatinine, umol/L |
83.0 (70.0−100.0)&
|
91.0 (76.0−115.0)&
|
0.143 |
| Echocardiographic parameters |
|
|
|
| Peak jet velocity, m/s |
5.1 ± 0.8 |
5.0 ± 0.8 |
0.366 |
| Mean pressure gradient, mmHg |
65.3 ± 21.5 |
62.3 ± 19.4 |
0.544 |
| Baseline ejection fraction, % |
54.8 ± 15.8 |
55.2 ± 14.6 |
0.883 |
| Baseline aortic regurgitation > mild |
28 (18.4%) |
8 (27.6%) |
0.257 |
| Baseline mitral regurgitation > mild |
26 (17.1%) |
7 (24.1%) |
0.369 |
| Anatomic parameters |
|
|
|
| AAo perimeter, mm |
112.3 ± 13.2 |
112.0 ± 11.6 |
0.915 |
| AAo angle, ° |
18.6 (13.8−22.6)&
|
24.2 (16.9−29.5)&
|
0.002 |
| Sinotubular junction perimeter, mm |
96.3 ± 13.3 |
98.0 ± 11.6 |
0.481 |
| Annular perimeter, mm |
77.6 ± 9.0 |
78.6 ± 8.5 |
0.569 |
| Membranous septum length, mm |
4.2 ± 2.1 |
3.8 ± 2.1 |
0.374 |
| Type-1 morphology |
57 (37.5%) |
22 (75.9%) |
< 0.001 |
| L-R fusion |
43 (75.4%) |
20 (90.9%) |
0.211*
|
| Calcified raphe |
32 (56.1%) |
10 (45.4%) |
0.394**
|
| HU-850 valve calcium volume, mm3
|
698.3 (355.3−1017.5)&
|
388.2 (244.7−742.7)&
|
0.019 |
| Excess leaflet calcification |
75 (49.3%) |
9 (31.0%) |
0.070 |
| HU-850 left ventricular outflow track calcium volume, mm3
|
0 (0.0−33.3)&
|
0 (0.0−10.0)&
|
0.188 |
| Membranous septum calcification |
16 (10.5%) |
1 (3.4%) |
0.316 |
| Aortomitral curtain calcification ≥ moderate |
19 (12.5%) |
6 (20.7%) |
0.246 |
| Preoperative electrocardiography |
|
|
|
| Atrial fibrillation |
20 (13.2%) |
4 (13.8%) |
0.926 |
| 1° atrioventricular block |
4 (2.6%) |
1 (3.4%) |
0.806 |
| Right bundle branch block |
6 (3.9%) |
3 (10.3%) |
0.146 |
| Left bundle branch block |
5 (3.3%) |
0 |
0.710 |
| Procedural and post-procedural characters |
|
|
|
| Pre-TAVI dilation |
151 (99.3%) |
28 (96.6%) |
0.296 |
| Post-TAVI dilation |
92 (60.5%) |
17 (59.6%) |
0.848 |
| Device |
|
|
0.392 |
| VenusA/VenusA-plus |
129 (84.9%) |
23 (79.3%) |
|
| Corevalve |
8 (5.3%) |
1 (3.4%) |
|
| VitaFlow |
10 (6.6%) |
2 (6.9%) |
|
| TaurasOne |
5 (3.3%) |
3 (10.3%) |
|
| Oversizing ratio, % |
6.5 ± 9.4 |
6.6 ± 9.0 |
0.928 |
| Implantation depth > membranous septum length |
96 (63.2%) |
26 (89.7%) |
0.005 |
